<br>        Inclusion criteria:<br><br>          -  Participants must be at least 18 years of age at the time of signing the informed<br>             consent.<br><br>          -  Participants with T2DM, and treated with diet and exercise.<br><br>          -  Hemoglobin A1c between 7.0% and 10.0% (inclusive) measured by the central laboratory<br>             at Screening.<br><br>        Exclusion criteria:<br><br>          -  Clinically relevant history of gastrointestinal disease associated with prolonged<br>             nausea and vomiting, including (but not limited to) gastroparesis, unstable and not<br>             controlled gastroesophageal reflux disease within 6 months prior to Screening or<br>             history of surgery affecting gastric emptying.<br><br>          -  History of pancreatitis (unless pancreatitis was related to gallstone and<br>             cholecystectomy has been performed) and pancreatitis during previous treatment with<br>             incretin therapies, chronic pancreatitis, and pancreatectomy.<br><br>          -  Personal or family history of Medullary Thyroidian Cancer (MTC) or genetic conditions<br>             that predisposes to MTC (eg multiple endocrine neoplasia syndromes).<br><br>          -  Retinopathy or maculopathy with one of the following treatments, either recent (within<br>             3 months of screening) or planned: intravitreal injections or laser or vitrectomy<br>             surgery.<br><br>          -  Body weight change of =5 kg within the last 3 months prior to Screening.<br><br>          -  Systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg at<br>             Randomization.<br><br>          -  End-stage renal disease as defined by estimated glomerular filtration rate (eGFR , by<br>             Modification of Diet in Renal Disease [MDRD]) of <15 mL/min/1.73 m2.<br><br>          -  Laboratory findings at the Screening Visit:<br><br>          -  Alanine aminotransferase (ALT ) or aspartate aminotransferase (AST ) >3 times the<br>             upper limit of the normal (ULN ) or total bilirubin >1.5 times the ULN (except in case<br>             of documented Gilbert's syndrome).<br><br>          -  Amylase and/or lipase: >3 times the ULN laboratory range.<br><br>          -  Calcitonin =5.9 pmol/L (20 pg/mL).<br><br>          -  Gastric surgery or other gastric procedures intended for weight loss within 2 years<br>             prior to Screening, or planned during study period.<br><br>          -  History of drug or alcohol abuse within 6 months prior to the time of Screening.<br><br>          -  Pregnant (demonstrated by serum pregnancy test at Screening) or breast-feeding women.<br><br>          -  Women of childbearing potential not willing to use highly effective method(s) of birth<br>             control during the study period and for at least 5 weeks after the last dose of study<br>             intervention.<br><br>        The above information is not intended to contain all considerations relevant to a patient's<br>        potential participation in a clinical trial.<br>